Effects of Omega-3 fatty acids for psychotic disorders

Effects of Omega-3 fatty acids for schizophrenia and at-risk mental state

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190054

Enrollment

134

Registered

2019-07-22

Start date

2019-08-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, at-risk mental state (ARMS) schizophrenia

Interventions

One-year administration of omega-3 polyunsaturated fatty acids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Schizophrenia patients, fulfilled the criteria of DSM-5, (2) ARMS patients, fulfilled the criteria of CAARMS(the Comprehensive Assessment of At-Risk Mental State)

Exclusion criteria

Exclusion criteria: (1)Organic mental disorders, including epilepsy, having the history of head injury or alcohol dependence, (2)bleeding tendency or GI bleeding, (3)Mental retardation, (4)Infant(aged below 15 years old)

Design outcomes

Primary

Measure	Time frame
(1)positive and negative syndrome scale(PANSS) (2)diagnosis (3)adverse reaction of Lotoriga	—

Secondary

Measure	Time frame
(1)concentration of fatty acids in erythrocyte membranes (2)Electroencephalogram(EEG):resting state, quantitative EEG, event related potentials(P300, mismatch negativity) (3)Neurocognition (4)Social cognition (5)Neuroimaging:MRI	—

Contacts

Public ContactYuko Higuchi

Toyama University Hospital

yhiguchi@med.u-toyama.ac.jp+81-764347323

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026